Breakthrough drug shows promise for painful skin condition in major trial

NCT ID NCT05620823

Completed Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

Summary

This Phase 3 clinical trial tested an oral medication called povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition. The study involved 608 participants who had not responded well to previous treatments. Over 12 weeks, researchers compared the drug to a placebo to see if it could reduce painful skin lesions and flares, followed by a longer 42-week extension period to assess continued safety and effectiveness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigative Site 00A

Innsbruck, 06020, Austria
Investigative Site AT300

Vienna, 01130, Austria
Investigative Site AT301

Vienna, 01100, Austria
Investigative Site AT302

Linz, 04020, Austria
Investigative Site AT304

Graz, 08036, Austria
Investigative Site AT305

Vienna, 01090, Austria
Investigative Site AT306

Innsbruck, 06020, Austria
Investigative Site BE300

Brussels, 01070, Belgium
Investigative Site BE301

Ghent, 09000, Belgium
Investigative Site BE302

Liège, 04000, Belgium
Investigative Site BE303

Namur, 05000, Belgium
Investigative Site BE304

Brussels, 01200, Belgium
Investigative Site BE305

Leuven, 03000, Belgium
Investigative Site BE306

Ghent, 09000, Belgium
Investigative Site CA301

Winnipeg, Manitoba, R3M 3Z4, Canada
Investigative Site CA302

Peterborough, Ontario, K9J 5K2, Canada
Investigative Site CA303

London, Ontario, N6H 5L5, Canada
Investigative Site CA304

Barrie, Ontario, L4M 1G7, Canada
Investigative Site CA306

Laval, Quebec, H7N 6L2, Canada
Investigative Site CA307

Montreal, Quebec, H2K 4L5, Canada
Investigative Site CA308

Hamilton, Ontario, L8L 3C3, Canada
Investigative Site CA309

Québec, Quebec, G1V 4T3, Canada
Investigative Site CZ300

Prague, 150 06, Czechia
Investigative Site CZ301

Ostrava - Poruba, 708 52, Czechia
Investigative Site DE300

Hanover, 30519, Germany
Investigative Site DE301

Frankfurt am Main, 60590, Germany
Investigative Site DE302

Dresden, 01307, Germany
Investigative Site DE303

Hamburg, 20246, Germany
Investigative Site DE304

Langenau, 89129, Germany
Investigative Site DE305

Darmstadt, 64283, Germany
Investigative Site DE306

Düsseldorf, 40225, Germany
Investigative Site DE307

Memmingen, 87700, Germany
Investigative Site ES300

Pontevedra, 36001, Spain
Investigative Site ES301

Granada, 18014, Spain
Investigative Site ES302

Badalona, 08916, Spain
Investigative Site ES303

Barcelona, 08003, Spain
Investigative Site ES304

Santiago de Compostela, 15706, Spain
Investigative Site ES305

Madrid, 28041, Spain
Investigative Site FR300

Paris, 75010, France
Investigative Site FR301

Saint-Priest-en-Jarez, 42270, France
Investigative Site FR302

Nantes, 44093, France
Investigative Site FR303

Brest, 29609, France
Investigative Site FR304

Marseille, 13385, France
Investigative Site FR305

Bordeaux, 33000, France
Investigative Site FR306

Toulouse, 31059, France
Investigative Site FR307

Le Mans, 72037, France
Investigative Site GR300

Athens, 12462, Greece
Investigative Site GR301

Thessaloniki, 54643, Greece
Investigative Site GR302

Thessaloniki, 56403, Greece
Investigative Site GR303

Athens, 16121, Greece
Investigative Site JP300

Kyoto, 602-8566, Japan
Investigative Site JP301

Nakagami-gun, 903-0215, Japan
Investigative Site JP302

Sendai, 980-8574, Japan
Investigative Site JP303

Niigata, 951-8520, Japan
Investigative Site JP304

Itabashi-ku, 173-8610, Japan
Investigative Site JP305

Kurume-shi, 830-0011, Japan
Investigative Site JP306

Tsukuba, 305-8576, Japan
Investigative Site JP307

Nishinomiya-shi, 663-8186, Japan
Investigative Site JP308

Sapporo, 060-8648, Japan
Investigative Site JP309

Shinjuku-ku, 160-0023, Japan
Investigative Site NL301

Rotterdam, 3015 GD, Netherlands
Investigative Site NL302

Breda, 4818 CK, Netherlands
Investigative Site NL303

Groningen, 9713 GZ, Netherlands
Investigative Site PL301

Wroclaw, 50-566, Poland
Investigative Site PL302

Wroclaw, 51-318, Poland
Investigative Site PL303

Poznan, 60-529, Poland
Investigative Site PL304

Ostrowiec, 27-400, Poland
Investigative Site US300

Plano, Texas, 75025, United States
Investigative Site US301

Portland, Oregon, 97223, United States
Investigative Site US302

St Louis, Missouri, 63110, United States
Investigative Site US303

Phoenix, Arizona, 85006, United States
Investigative Site US304

Boston, Massachusetts, 02215, United States
Investigative Site US306

Boca Raton, Florida, 33486, United States
Investigative Site US307

Fort Smith, Arkansas, 72916, United States
Investigative Site US308

Spokane, Washington, 99202, United States
Investigative Site US310

Brighton, Massachusetts, 02135, United States
Investigative Site US311

Marietta, Georgia, 30060-1047, United States
Investigative Site US312

Cleveland, Ohio, 44106, United States
Investigative Site US313

Norfolk, Virginia, 23502, United States
Investigative Site US314

Cincinnati, Ohio, 45219, United States
Investigative Site US315

Laguna Niguel, California, 92677, United States
Investigative Site US316

Orlando, Florida, 32819, United States
Investigative Site US317

Hialeah, Florida, 33012-3618, United States
Investigative Site US318

Beverly, Massachusetts, 01915, United States
Investigative Site US319

Skokie, Illinois, 60077, United States
Investigative Site US320

Boca Raton, Florida, 33486, United States
Investigative Site US321

North Miami Beach, Florida, 33162-4708, United States
Investigative Site US323

San Francisco, California, 94118, United States
Investigative Site US324

Kew Gardens, New York, 11415, United States
Investigative Site US325

Columbia, Maryland, 21045, United States
Investigative Site US326

Los Angeles, California, 90045, United States
Investigative Site US327

Chicago, Illinois, 60612, United States
Investigative Site US328

Tampa, Florida, 33612, United States
Investigative Site US330

Boardman, Ohio, 44512, United States
Investigative Site US331

Albuquerque, New Mexico, 87102, United States
Investigative Site US333

Baltimore, Maryland, 21287, United States
Investigative Site US334

Metairie, Louisiana, 70006, United States
Investigative Site US335

Arkansas City, Arkansas, 72758, United States
Investigative Site US336

Tampa, Florida, 33613, United States
Investigative Site US337

Indianapolis, Indiana, 46250, United States
Investigative Site US338

Margate, Florida, 33063, United States
Investigative Site US339

Bexley, Ohio, 43209, United States
Investigative Site US340

Bellaire, Texas, 77401, United States
Investigative Site US341

Bowling Green, Kentucky, 42103, United States

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA (HS)